LAG3 and TIGIT Expression on Tumor Infiltrating Lymphocytes in Cutaneous Melanoma.

Melanoma is widely recognized to be an immunogenic tumor that often contains tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME).During cancer progression, expression of ligands that bind immune checkpoint (IC) proteins, such as PD1, expressed on the surface of TILs, hinder them from exerting their antitumor functions. TILs consist of a heterogenous group of immune cells and their presence is associated with an improved overall survival (OS) in melanoma patients. Introduction of IC inhibitors has revolutionized management and prognosis of advanced melanoma. Unfortunately, the response rates have continued to be limited, resulting in growing interest in characterizing novel IC proteins, and developing combination therapy that includes inhibitors against multiple IC proteins.In a regional cohort of 166 patients diagnosed with cutaneous superficial spreading melanoma (SSM) with different degree of TILs, we investigated the tumor-immune associated gene expression profile using NanoString Technology. We used multiplex immunofluorescence (mIF) staining in a subset of tumors (N=7), combining IC proteins TIGIT and LAG3 with a melanoma cell marker (SOX10) and immune cell markers (CD8 (cytotoxic T cells), CD4 (T helper cells), FOXP3 (regulatory T cells/Tregs), PAX5 (B cells), and CD56 (NK/NKT cells)) and IC protein PD1.We found upregulation of 91 differentially expressed genes, including IC proteins, LAG3 and TIGIT in melanomas with brisk TILs compared to tumors where TILs were absent. mIF staining revealed LAG3 and TIGIT expression in the majority of CD8+ T cells. Only few Tregs and CD4+ T cells expressed LAG3, whereas majority of them expressed TIGIT. LAG3 and TIGIT were expressed in a small fraction of the NK/NKT cells and lacked in the B cells. The majority of PD1+ cells co-localized with LAG3 and TIGIT.We report a variable expression of LAG3 and TIGIT on TILs subtypes and a coeval occurrence with PD1. This knowledge places LAG3 and TIGIT in spatial and cellular context in melanoma. The data suggest that targeting multiple IC proteins might help to overcome the current challenges with IC therapies.